Bioject Medical Technologies Enters Supply Agreement with Chronimed, Inc.

Strategic Insights -

Bioject Medical Technologies, Inc. (BJCT) has partnered with Chronimed, Inc. (CHMD) to supply Biojector 2000 (B-2000) needle-free systems and related accessories. The agreement aims to distribute the products to eligible patients using Fuzeon, an AIDS drug developed by Trimeris, Inc. in collaboration with Roche. This collaboration aims to improve the lives of people with HIV/AIDS by offering a needle-free drug delivery option.

Key Takeaways:

  • The agreement between Bioject Medical Technologies and Chronimed, Inc. will provide eligible patients with access to Biojector 2000 (B-2000) needle-free systems and related accessories.
  • The systems will be used to administer Fuzeon, a fusion inhibitor for the treatment of HIV, to patients who are experiencing tolerability problems with needle-based therapy.
  • Early data has shown that patients who received a single dose of Fuzeon with the B-2000 achieved equivalent drug levels in the blood as those who used the standard needle and syringe.
  • A small cohort of 12 patients experienced improved tolerability when switching from needle-based to needle-free administration of Fuzeon.
  • Jim O'Shea, Bioject's chairman, president, and CEO expressed enthusiasm for the partnership, citing the B-2000's ability to deliver millions of injections since its approval in 1994.
  • Tony Zappa, Chronimed's executive VP of operations, highlighted the company's experience with injection-related issues and its comprehensive evaluation and support program for Fuzeon patients.

Statistics:

  • Since its approval in 1994, the B-2000 has been used to deliver millions of injections in various healthcare settings.
  • Early data presented at the HIV DART - Frontiers in Drug Development for Antiretroviral Therapies conference showed that patients who used the B-2000 achieved equivalent drug levels in the blood as those who used the standard needle and syringe.
  • A small cohort of 12 patients experienced improved tolerability when switching from needle-based to needle-free administration of Fuzeon for up to 4 weeks.

Sources:

  • Bioject Medical Technologies, Inc.
  • Chronimed, Inc.
  • Trimeris, Inc.
  • Roche
  • Health & Medicine Week
  • NewsRx.com & NewsRx.net
  • British Columbia Centre for Excellence in HIV/AIDS